LATEST TRIALS

  • Prostate Cancer
    Safety and pharmacokinetics of ODM-208 in patients with metastatic castration-resistant prostate cancer
  • Colorectal Cancer
    Protocol for treatment under Hospital Exemption:T cell receptor based therapy of metastatic colorectal cancer with mRNA-engineered T cells targeting transforming growth factor beta receptor type II (TGFβII)
  • Breast Cancer
    ICON CA209-9FN: A randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with luminal B breast cancer

NORDIC COOPERATION

Norway Norway Sweden Finland Aarhus Herlev Copenhagen